Tirzepatide Cost: A Source-Checked 2026 Guide

How much can tirzepatide cost each month?

“Tirzepatide cost” is not one price. Tirzepatide is the active ingredient in Zepbound and Mounjaro, but those products have different FDA-approved uses, coverage rules, savings programs, devices, and purchase channels. Lilly’s pricing page states a Zepbound list-price range of $499 to $1,086.37 per fill. Its separate direct-to-patient schedule lists 2.5 mg at $299, 5 mg at $399, 7.5 mg at $499, and 10 mg, 12.5 mg, and 15 mg at $699 for a 28-day supply. Those figures are not interchangeable. A list price is a manufacturer wholesale benchmark, while direct self-pay pricing is a specific cash purchase path with its own prescription, format, and fulfillment conditions.

Lilly’s Mounjaro pricing page states a list price of $1,112.16 per fill, defined there as four pens or one month. That does not mean every patient pays $1,112.16. An insurer may negotiate a price and assign a copay or coinsurance; a deductible may apply; an eligible commercial patient may qualify for a savings program; or a patient may use another permitted self-pay route. The honest comparison is therefore not “Zepbound costs X and Mounjaro costs Y.” It is a matrix of product, dose, device, payment path, eligibility, refill timing, taxes, fees, and what the quoted supply includes.

This guide uses manufacturer-published figures checked July 31, 2026, and labels each figure by its actual payment path. Prices and program rules change. Before paying, reopen the first-party source, confirm that the displayed dose and device match the prescription, and save the date and exact terms. A low headline price that applies only to a starting dose, a different device, a first purchase, or an eligible insurance group is not a dependable estimate for later months.

Why can two tirzepatide prices be so different?

The first distinction is list price versus patient price. Lilly defines list price, also called wholesale acquisition cost, as the price at which it sells a product to wholesalers. A patient’s pharmacy bill can differ because of insurer-negotiated pricing, deductibles, copays, coinsurance, pharmacy charges, discounts, or assistance. Quoting the list price without this context can overstate what an insured patient pays. Quoting only the lowest savings amount can understate what an ineligible patient owes. Both errors disappear when every number is labeled by source and eligibility.

The second distinction is device and dose. Zepbound has multiple presentations, including single-dose pens, vials, and a single-patient-use KwikPen. Lilly’s July 2026 pages identify six strengths. The 2.5 mg starting dose has the lowest published direct self-pay amount, but the FDA label states that 2.5 mg is a starting dose rather than an approved maintenance dose. A person whose prescriber later selects another dose should not build a long-term budget from the starting-dose price alone. This is cost context, not dosing advice; dose selection belongs to a licensed clinician.

The third distinction is a regular price versus a conditional offer. Lilly’s Zepbound savings terms state a $449 purchase offer for certain 7.5 mg through 15 mg KwikPen purchases, but continued eligibility requires a refill purchase within 45 days of the prior delivery or receipt. The same terms list regular monthly KwikPen prices of $499 at 7.5 mg and $699 at 10 mg through 15 mg. A responsible table shows both the regular amount and the condition instead of presenting $449 as an unconditional ongoing price.

Finally, a telehealth program quote may bundle services that a medication-only price does not: an intake, clinician review, support, membership, shipping, or laboratory work. It may also omit a medication charge until after evaluation. Compare the full first-period charge, recurring charge, medication status, refill assumptions, and cancellation terms. Never assume that “starting at” means the total amount needed to receive a prescription or a full month of medication.

What do the current Zepbound self-pay prices include?

The pricing schedule is useful because it removes a common ambiguity: the monthly amount changes with dose. GLP Clinic Scout normalized each amount to Lilly’s stated 28-day month and preserved the device and dose qualifiers. We did not average the six values into a single “typical” cost because that would hide the difference between the starting dose and higher strengths. We also did not treat a manufacturer cash price as an insurance estimate. The owned comparison table is a structured summary of dated source facts, not a promise that a particular patient can buy at a particular amount.

The savings page adds another distinction between a regular self-pay price and a purchase offer. For eligible KwikPen purchases, Lilly states that certain higher doses can receive a $449 purchase offer, with refill timing and other terms. If the timing condition is missed, the purchase offer may not apply. The page says additional taxes and fees may apply and that program terms can be changed or ended. Therefore a budget should include the regular price as the conservative reference and treat any lower conditional amount as dependent on verified eligibility at the time of purchase.

The manufacturer also states that Zepbound requires a prescription. A public price page does not establish that the medicine is medically appropriate for an individual. The FDA label includes a boxed warning, contraindications, warnings, and medication-specific instructions. Anyone comparing costs should use the price table only after or alongside a real clinician-led prescription decision, not as a substitute for it.

How do Mounjaro and Zepbound cost comparisons differ?

The shared ingredient does not make the products interchangeable for every purpose. The 2026 FDA Zepbound label identifies chronic weight management in qualifying adults and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity among its indications. Mounjaro’s labeling centers on type 2 diabetes. Coverage, prior authorization, savings eligibility, and pharmacy adjudication can therefore differ even when a consumer searches only for “tirzepatide.” A cost page should preserve the product name and indication context rather than collapsing both brands into one generic price.

Lilly’s Mounjaro page says its $1,112.16 list price covers one fill of four pens, defined as a one-month supply. It also says actual cost largely depends on the prescription drug insurance plan and notes commercial savings options with eligibility rules. The Zepbound page publishes a broader range because it includes direct-to-patient formats and prices as well as the upper list-price amount. Comparing the lowest Zepbound self-pay number with Mounjaro’s wholesale list price would mix unlike categories and produce a misleading gap.

For a fair comparison, identify the exact prescribed product, then capture the same price class for each option: list price versus list price, direct self-pay versus direct self-pay, or verified patient-specific insurance estimate versus another patient-specific estimate. If one matching category is unavailable, mark it unresolved. Do not estimate it from a coupon site, a different dose, or a different product.

How can insurance and savings change the amount paid?

Insurance cost is patient- and plan-specific. The useful questions are whether the prescribed product is on the formulary, whether prior authorization or step requirements apply, how the deductible affects the current fill, and whether the pharmacy is in network. The manufacturer page advises contacting the insurer for the most accurate details. Save any coverage response and ask whether the quoted amount applies before or after the deductible. A verbal estimate can change when the pharmacy claim is processed.

Manufacturer savings terms divide patients by insurance status and program eligibility. Government beneficiaries may be excluded from some commercial savings programs, while separate pathways may exist under specific public-program rules. The July 2026 Zepbound page also describes a Medicare GLP-1 Bridge path for certain eligible patients, but explicitly says that it is not a guarantee of coverage. Do not generalize one pathway to everyone with Medicare, Medicaid, VA, DoD, TRICARE, or another public benefit.

Expiration dates and refill limits matter. Lilly’s published Zepbound savings terms reviewed for this guide expire December 31, 2026 and permit changes or termination. Some offers have annual fill limits, maximum monthly or annual savings, device restrictions, and timing requirements. A price comparison should therefore include a “terms checked” date and a reminder to reverify before each refill. Stale savings language can turn a seemingly precise annual estimate into fiction.

What should be verified before paying for tirzepatide?

Start with product identity. Confirm whether the offer is for FDA-approved Zepbound or Mounjaro, another lawful product category described accurately, or an ambiguous “tirzepatide” listing. The FDA label states that Zepbound contains tirzepatide and does not recommend coadministration with other tirzepatide-containing products or GLP-1 receptor agonists. A legitimate commercial page should not blur brand, ingredient, compounder, or pharmacy identity in a way that prevents an informed comparison.

Next, separate care from fulfillment. Record the telehealth company or website owner, the medical group if named, the clinician review, and the dispensing pharmacy. Check the pharmacy against the relevant state board before payment when its identity is available. If the pharmacy will not be disclosed until later, record that limitation instead of converting it into a verified claim. A checkout logo or attractive testimonial does not prove prescribing authority, pharmacy licensure, or product origin.

Then normalize the economics. Write down the intake charge, recurring membership, medication charge, shipping, laboratory requirements, cancellation deadline, refund rule, refill interval, and any price change by dose. Ask for an itemized total for the first 28 days and a realistic recurring amount at the prescribed maintenance dose, while recognizing that only a clinician can determine dose. If a lower price depends on insurance denial, a coupon, a refill within 45 days, or another condition, put that condition beside the number.

Finally, keep the medical boundary clear. Cost research cannot determine whether tirzepatide is appropriate, safe, or indicated for an individual. Review the current FDA Medication Guide and prescribing information, share health history and medications with a qualified clinician, and use emergency or urgent care when symptoms warrant it. GLP Clinic Scout’s role here is to organize public pricing and verification fields, not to diagnose, prescribe, alter a dose, or rank a treatment for a specific reader.